Products & Portfolio (3)
ABEMACICLIB
abemaciclib
Pre-Launch
SMTABLET
cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.
breast cancer
CARFILZOMIB
carfilzomib
Pre-Launch
INTRAVENOUS · POWDER
N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors.
refractory multiple myelomadexamethasonemyeloma
LASMIDITAN
lasmiditan
Pre-Launch
TABLET
Pipeline & Clinical Trials
Gefitinib
Lung CancerClinical Trials (1)
NCT03381430Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
N/AN/A
Clinical Trials (1)
NCT03195569To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer
N/APost-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
NSCLCClinical Trials (1)
NCT06644495Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
N/AThe test olaparib tablet
NeoplasmsClinical Trials (1)
NCT05860530Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
N/AHigh dose or normal dose staphylococcus albicans
Pulmonary Disease, Chronic ObstructiveClinical Trials (1)
NCT05543343Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
N/AMontelukast sodium oral thin films with water
Healthy VolunteersClinical Trials (1)
NCT05531994Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers
N/AStandard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion
Neonatal Alloimmune ThrombocytopeniaClinical Trials (1)
NCT02934906Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant Women
N/APost-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Adverse Drug ReactionMontelukast sodium oral thin films without water
Healthy VolunteersClinical Trials (1)
NCT05528198Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers
N/AAntiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe
HIV InfectionsFL058
HealthyClinical Trials (1)
NCT05058118Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD)
Phase 1QLF3108
Advanced Solid TumorClinical Trials (1)
NCT06019013A Study of QLF3108 in Participants With Advanced Solid Tumor
Phase 1QL2302
Healthy ParticipantsClinical Trials (1)
NCT07327697A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects
Phase 1IS-5-MN R
BioequivalenceClinical Trials (1)
NCT03557580A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects
Phase 1QL2109
Multiple MyelomaClinical Trials (1)
NCT07400744A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Phase 1QLS1410
Uncontrolled HypertensionClinical Trials (1)
NCT07358858A Food Effect Study of QLS1410 in Healthy Chinese Adults
Phase 1[14C]Iruplinalkib
HealthyClinical Trials (1)
NCT05716126Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers
Phase 1QL1604 injection
Advanced Solid TumorsClinical Trials (1)
NCT05649761A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
Phase 1QLS31904
Advanced Solid TumorClinical Trials (1)
NCT05461287Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
Phase 1QLS1103
Advanced Solid TumorClinical Trials (1)
NCT05884801Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
Phase 1The test octreotide microsphere
Healthy VolunteersClinical Trials (1)
NCT06254235Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers
Phase 1QLS1304 tablet
Advanced Malignant TumorClinical Trials (1)
NCT06823609Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
Phase 1QL2108 injection
Atopic DermatitisClinical Trials (1)
NCT06614907A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
Phase 1QLS4131 for Injection.
Systemic Lupus ErythematosusClinical Trials (1)
NCT07001839A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus
Phase 1QLS1410
Uncontrolled HypertensionClinical Trials (1)
NCT07152444A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension
Phase 1Phase 1
Clinical Trials (1)
NCT03312283Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
Phase 1QL1604
Advanced Solid TumorClinical Trials (1)
NCT05801094A Phase I Study of QL1604 for Advanced Solid Tumors
Phase 1QLH11811
Non-small Cell Lung CancerClinical Trials (1)
NCT05555212To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation
Phase 1FL058 500mg and Meropenem 1000mg（ IV 120min）
HealthyClinical Trials (1)
NCT05058105Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)
Phase 1QL1706H
Advanced Solid TumorsClinical Trials (1)
NCT06047431A Study of QL1706H in Patients With Advanced Solid Tumors
Phase 1QLS12004
Advanced Solid TumorClinical Trials (1)
NCT05829616A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors
Phase 1QLS1209
Advanced Solid TumorClinical Trials (1)
NCT06872580A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors
Phase 1QL1206
Healthy PeopleClinical Trials (1)
NCT04213105Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults
Phase 1Capecitabine
Colon CancerClinical Trials (1)
NCT03435666A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition
Phase 1Clinical Trials (1)
NCT07331545Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults
Phase 1QLF32004
Advanced TumorClinical Trials (1)
NCT05108779QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
Phase 1QL-007 tablet
Chronic Hepatitis bClinical Trials (1)
NCT03244085A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients
Phase 1QL1203
Healthy MalesClinical Trials (1)
NCT04234594Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
Phase 1QLS4131 Injection
Relapsed or Refractory Multiple MyelomaClinical Trials (1)
NCT06500507A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Phase 1QLS31905
Advanced Solid TumorsClinical Trials (1)
NCT05278832A Study of QLS31905 in Patients With Advanced Solid Tumors
Phase 1QL1101
TumorClinical Trials (1)
NCT06232902A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
Phase 1QL1706
Advanced Malignant TumorClinical Trials (1)
NCT04296994A Study of QL1706 in Subjects With Advanced Malignant Tumor
Phase 1QLH12016
Prostate CancerClinical Trials (1)
NCT05973149Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1Phase 1
Clinical Trials (1)
NCT05703204A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1QLF31907
Solid TumorClinical Trials (1)
NCT05150405A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
Phase 1QL-007 tablet
Chronic Hepatitis bClinical Trials (1)
NCT03770624A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA
Phase 1QLS5316
Solid TumorsClinical Trials (1)
NCT07358884First in Human Study of QLS5316 in Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05488821Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
Phase 1QLS1128 A-Dose 1~5 and Ritonavir
COVID-19Clinical Trials (1)
NCT05458076A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants
Phase 1Phase 1
Clinical Trials (1)
NCT07178171A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Phase 1Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Founded: 1958
Portfolio: 3 approved products, 48 clinical trials
Top TAs: Oncology
Portfolio Health
Pre-Launch3 (100%)
3 total products